ACE and COVID-19: Longer term follow‐up is needed to investigate clinical outcomes in patients with a history of COVID‐19 treated with RASi—previous studies in patients without COVID‐19 demonstrated that angiotensin‐converting enzyme inhibition or ARB‐based treatment is associated with lower mortality in the follow‐up after AKI.58